Nonvaccine human papillomavirus genotype common in women with HIV failing cervical precancer treatment. (15th November 2021)

• Record Type: Journal Article
• Authors: Carlander, Christina; Lagheden, Camilla; Eklund, Carina; Nordqvist Kleppe, Sara; Dzabic, Mensur; Wagner, Philippe; Sparén, Pär; Dillner, Joakim
• Is Part Of: AIDS. Volume 35:Number 14(2021)
• Page Start: 2367
• Page End: 2374
• Publication Date: 2021-11-15
• Subjects: cervical intraepithelial lesions -- excision treatment outcome -- HIV -- human papillomavirus -- treatment; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000003026
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Supplemental Digital Content is available in the text Abstract : Objective: The aim of this study was to assess failure after treatment of high-grade cervical intraepithelial neoplasia (CIN2+) by HIV status and human papillomavirus (HPV) type. Design: A population-based register study. Methods: The Swedish National HIV Registry, the Swedish Population Registry and the Swedish National Cervical Screening Registry were linked to identify all women in Stockholm and Gothenburg counties (Sweden) living with HIV and diagnosed with CIN2+ sometime between 1983 and 2014 ( n = 179). HIV-negative controls with CIN2+, were matched (2 : 1) for country of birth. CIN2+ biopsies were retrieved from biobanks and genotyped. Absolute risk and adjusted odds ratios (adjOR) of treatment failure by HIV status given HPV type (HPV16/18 vs. non-HPV16/18) were calculated. Results: HPV16 (32%) and HPV35 (24%) dominated in women living with HIV (WLWH) with failure, HPV35 mainly in women born in sub-Saharan Africa (67%). The absolute risk of failure in women with HPV16/18 was 26% [95% confidence interval (95% CI) 14–44] in WLWH and 12% in HIV-negative (95% CI 7–19). The absolute risk of failure in women with non-HPV16/18 was 20% (95% CI 12–31) in WLWH and 5% in HIV-negative (95% CI 2–11). WLWH with non-HPV16/18 were six times more likely to fail than HIV-negative (adjOR 6.1, 95% CI 2.0–18.6). Conclusion: HPV35, not included in current HPV vaccines, was the second most common type in WLWH with failure. WLWH with non-HPV16/18 were six times more likely to fail than HIV-negative. This could have implications for surveillance and vaccination post CIN2+ treatment, particularly in WLWH from sub-Saharan Africa.